Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Profund Advisors LLC

Profund Advisors LLC cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 19.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,364 shares of the medical equipment provider’s stock after selling 836 shares during the period. Profund Advisors LLC’s holdings in Lantheus were worth $270,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Janney Montgomery Scott LLC boosted its position in Lantheus by 6.2% during the 4th quarter. Janney Montgomery Scott LLC now owns 8,005 shares of the medical equipment provider’s stock worth $497,000 after acquiring an additional 467 shares during the period. Norges Bank bought a new stake in shares of Lantheus during the 4th quarter worth about $29,956,000. PNC Financial Services Group Inc. lifted its stake in shares of Lantheus by 14.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,613 shares of the medical equipment provider’s stock worth $596,000 after acquiring an additional 1,202 shares during the period. TD Asset Management Inc boosted its holdings in shares of Lantheus by 16.4% in the fourth quarter. TD Asset Management Inc now owns 94,172 shares of the medical equipment provider’s stock valued at $5,839,000 after acquiring an additional 13,280 shares in the last quarter. Finally, Olympiad Research LP acquired a new position in shares of Lantheus during the fourth quarter valued at approximately $203,000. 99.06% of the stock is owned by institutional investors.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $107.36 on Friday. The company’s fifty day moving average is $104.45 and its two-hundred day moving average is $85.69. The company has a market cap of $7.44 billion, a P/E ratio of 16.39 and a beta of 0.50. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The business had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. During the same period in the previous year, the firm posted $1.40 earnings per share. The firm’s quarterly revenue was up 22.5% on a year-over-year basis. Equities analysts expect that Lantheus Holdings, Inc. will post 5.99 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Leerink Partners upped their target price on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. B. Riley boosted their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Redburn Atlantic started coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective for the company. Truist Financial dropped their target price on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Finally, JMP Securities decreased their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $126.00.

Insider Transactions at Lantheus

In related news, President Paul Blanchfield sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now directly owns 98,980 shares of the company’s stock, valued at $9,540,682.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares of the company’s stock, valued at $9,540,682.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Mary Anne Heino sold 10,481 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $95.50, for a total value of $1,000,935.50. Following the completion of the transaction, the director now directly owns 454,923 shares in the company, valued at $43,445,146.50. The disclosure for this sale can be found here. Insiders sold 40,852 shares of company stock valued at $3,922,001 over the last three months. 1.50% of the stock is owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.